SCHEMBL24255327

SCHEMBL24255327

CN1CCC(c2ccc(Nc3ncc(Cl)c(NCC4CCOCC4)n3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 9/20 0.62
ALK Q9UM73 2/20 0.62
CHEK1 O14757 1/20 0.62
JAK2 O60674 1/20 0.62
ABL1 P00519 1/20 0.62
LCK P06239 1/20 0.62
ROS1 P08922 1/20 0.62
FGFR1 P11362 1/20 0.62
SRC P12931 1/20 0.62
TYK2 P29597 1/20 0.62
STAT6 P42226 1/20 0.51
STK17A Q9UEE5 1/20 0.50
SYK P43405 1/20 0.50
LRRK2 Q5S007 2/20 0.48
BRD4 O60885 2/20 0.48
WEE1 P30291 1/20 0.48
KCNH2 Q12809 1/20 0.47
NTRK1 P04629 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26270103 0.91 TNK2 (0.58) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24255244 0.91 TNK2 (0.58) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24255222 0.89 TNK2 (0.75) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24258126 0.86 TNK2 (0.61) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24255328 0.86 TNK2 (0.55) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24255507 0.85 LRRK2 (0.64) TNK2ALKJAK2SRCLRRK2
SCHEMBL24255227 0.83 LRRK2 (0.55) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24255313 0.82 TNK2 (0.57) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24258095 0.81 JAK3 (0.57) TNK2ALKCHEK1JAK2ABL1
SCHEMBL24258131 0.81 TNK2 (0.53) TNK2ALKCHEK1JAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295129-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH 2023-09-21 US disclosed
US-20230295129-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH 2023-09-21 US disclosed
WO-2022036312-A2 INHIBITORS OF ACK1/TNK1 TYROSINE KINASE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295129-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE TNK1, TNK2, TNNI3K TNK2 2/4885ALK 272/4885CHEK1 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.